<DOC>
	<DOCNO>NCT01452009</DOCNO>
	<brief_summary>A multi-center , observer-masked , randomize , parallel group efficacy safety study TRAVATAN® versus new formulation Travoprost Ophthalmic Solution , 0.004 %</brief_summary>
	<brief_title>Three Month Safety Efficacy Study TRAVATAN® Versus Travoprost Ophthalmic Solution , 0.004 %</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Patients 18 year age old 2 . Either gender 3 . Any race/ethnicity 4 . Diagnosed openangle glaucoma ( include patient pseudoexfoliation pigment dispersion ) ocular hypertension 1 . Patients form glaucoma openangle glaucoma . 2 . Patients central cornea thickness great 620 μm 3 . Patients Shaffer angle Grade &lt; 2 4 . Patients cup/disc ratio great 0.80 5 . Patients severe central visual field loss 6 . BestCorrected Visual Acuity score worse 55 ETDRS letter ( 20/80 Snellen equivalent ) 7 . Chronic , recurrent severe inflammatory eye disease 8 . Clinically significant progressive retinal disease 9 . Other ocular pathology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>open angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
</DOC>